Trials / Completed
CompletedNCT03081637
FLNA in HCC Patients
Filamin A Expression in HCC Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 115 (actual)
- Sponsor
- University of Milan · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The risk of recurrence after hepatectomy for hepatocellular carcinoma (HCC) is very high. Having a predictive marker of early recurrence (ER) would be desirable to personalize the follow-up and possibly develop new targeted therapy. The aim of this study was to test the expression of Filamin A (FLNA) in a cohort of patients operated for HCC.
Detailed description
A consecutive cohort of resected HCC patients will be analyzed. Several different prognostic factors, including FLNA expression, will be tested against the risk of ER. FLNA expression will be analyzed with immunohistochemistry in the intra-tumoral and extra-tumoral tissue compartments using a dedicated tissue microarray.
Conditions
Timeline
- Start date
- 2004-01-01
- Primary completion
- 2014-12-31
- Completion
- 2017-03-02
- First posted
- 2017-03-16
- Last updated
- 2017-06-01
Source: ClinicalTrials.gov record NCT03081637. Inclusion in this directory is not an endorsement.